Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Altshuler, L. L. Articles by Whybrow, P. C. Search for Related Content PubMed Citation Articles by Altshuler, L. L. Articles by Whybrow, P. C. Depression Antidepressants Other Somatic Therapy

Does Thyroid Supplementation Accelerate Tricyclic Antidepressant Response? A Review and Meta-Analysis of the Literature

OBJECTIVE: The delayed onset of therapeutic response to antidepressants remains a major problem in the treatment of depression. Among the strategies to accelerate response to treatment, the early addition of thyroid hormone to antidepressants has been suggested as a viable method. The authors performed a meta-analysis of the literature on the use of thyroid hormone supplementation to accelerate the treatment of depression to determine whether there is sufficient evidence to support the clinical efficacy of this strategy. METHOD: Both a computer-aided search of the National Library of Medicine MEDLINE and an intensive search by hand were conducted to identify all double-blind, placebo-controlled studies assessing the concomitant administration of thyroid hormone and antidepressant to accelerate clinical response in patients with nonrefractory depression. RESULTS: Six studies were identified. All were conducted with triiodothyronine (T₃) and a tricyclic antidepressant. Five of the six studies found T₃ to be significantly more effective than placebo in accelerating clinical response. The pooled, weighted effect size index was 0.58, and the average effect was highly significant. Further, the effects of T₃ acceleration were greater as the percentage of women participating in the study increased. CONCLUSIONS: This meta-analysis supports the efficacy of T₃ in accelerating clinical response to tricyclic antidepressants in patients with nonrefractory depression. Furthermore, women may be more likely than men to benefit from this intervention.

This article has been cited by other articles:

				S. M. Kansagra, C. R. McCudden, and M. S. Willis The Challenges and Complexities of Thyroid Hormone Replacement Lab Med, June 1, 2010; 41(6): 338 - 348. [Abstract] [Full Text] [PDF]

				R. Cooper-Kazaz, J. T. Apter, R. Cohen, L. Karagichev, S. Muhammed-Moussa, D. Grupper, T. Drori, M. E. Newman, H. A. Sackeim, B. Glaser, et al. Combined Treatment With Sertraline and Liothyronine in Major Depression: A Randomized, Double-blind, Placebo-Controlled Trial Arch Gen Psychiatry, June 1, 2007; 64(6): 679 - 688. [Abstract] [Full Text] [PDF]

				A. A. Nierenberg, M. Fava, M. H. Trivedi, S. R. Wisniewski, M. E. Thase, P. J. McGrath, J. E. Alpert, D. Warden, J. F. Luther, G. Niederehe, et al. A Comparison of Lithium and T3 Augmentation Following Two Failed Medication Treatments for Depression: A STAR*D Report Am J Psychiatry, September 1, 2006; 163(9): 1519 - 1530. [Abstract] [Full Text] [PDF]

				P. Saravanan, T. J. Visser, and C. M. Dayan Psychological Well-Being Correlates with Free Thyroxine But Not Free 3,5,3'-Triiodothyronine Levels in Patients on Thyroid Hormone Replacement J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3389 - 3393. [Abstract] [Full Text] [PDF]

				C. DeBattista Augmentation and combination strategies for depression J Psychopharmacol, May 1, 2006; 20(3_suppl): 11 - 18. [Abstract] [PDF]

				A. Kalsbeek, R. M. Buijs, R. van Schaik, E. Kaptein, T. J. Visser, B. Z. Doulabi, and E. Fliers Daily Variations in Type II Iodothyronine Deiodinase Activity in the Rat Brain as Controlled by the Biological Clock Endocrinology, March 1, 2005; 146(3): 1418 - 1427. [Abstract] [Full Text] [PDF]

				L. J. Fochtmann and A. J. Gelenberg Guideline Watch: Practice Guideline for the Treatment of Patients With Major Depressive Disorder, 2nd Edition Focus, January 1, 2005; 3(1): 34 - 42. [Full Text] [PDF]

				B. C. Appelhof, J. P. Brouwer, R. van Dyck, E. Fliers, W. J. G. Hoogendijk, J. Huyser, A. H. Schene, J. G. P. Tijssen, and W. M. Wiersinga Triiodothyronine Addition to Paroxetine in the Treatment of Major Depressive Disorder J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6271 - 6276. [Abstract] [Full Text] [PDF]

				A. M. Sawka, H. C. Gerstein, M. J. Marriott, G. M. MacQueen, and R. T. Joffe Does a Combination Regimen of Thyroxine (T4) and 3,5,3'-Triiodothyronine Improve Depressive Symptoms Better Than T4 Alone in Patients with Hypothyroidism? Results of a Double-Blind, Randomized, Controlled Trial J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4551 - 4555. [Abstract] [Full Text] [PDF]

				R. A. Remick Diagnosis and management of depression in primary care: a clinical update and review Can. Med. Assoc. J., November 26, 2002; 167(11): 1253 - 1260. [Abstract] [Full Text] [PDF]

				I. BERLIN and E. CORRUBLE Thyroid Hormones and Antidepressant Response Am J Psychiatry, August 1, 2002; 159(8): 1441 - 1441. [Full Text]

				Other Articles Noted Evid. Based Ment. Health, May 1, 2002; 5(2): 40 - 40. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2001 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us